论文部分内容阅读
目的:对甲氨蝶呤与来氟米特联用治疗类风湿性关节炎的临床疗效及安全性予以探讨。方法:将2015年1月到2016年2月我院门诊治疗的86例类风湿性关节炎患者纳入此次研究中,基于随机分组法分成联合组和常规组,每组43例;常规组单一应用甲氨蝶呤治疗,联合组在此基础上加用来氟米特治疗,对两组临床疗效及不良反应发生情况予以评价及比较分析。结果:通过分析,联合组临床总有效率为95.4%,要显著高于常规组的81.4%,差异有统计意义(P<0.05);在治疗中,两组均未出现明显不良反应,无差异(P>0.05)。结论:在类风湿性关节炎临床治疗中,联合应用甲氨蝶呤与来氟米特的疗效更为确切,不良反应少,安全性较高,是一个合理、有效、安全的治疗方法。
Objective: To investigate the clinical efficacy and safety of methotrexate combined with leflunomide in the treatment of rheumatoid arthritis. Methods: From January 2015 to February 2016, 86 patients with rheumatoid arthritis treated in our hospital were enrolled in this study. They were divided into the combined group and the conventional group based on the randomized group method, with 43 cases in each group. The single group Application of methotrexate treatment, the combination group on the basis of leflunomide treatment, the two groups of clinical efficacy and adverse reactions were evaluated and compared. Results: Through analysis, the total clinical effective rate in the combined group was 95.4%, which was significantly higher than that in the conventional group (81.4%, P <0.05). No significant adverse reactions were found in the two groups (P> 0.05). Conclusion: In the clinical treatment of rheumatoid arthritis, combination of methotrexate and leflunomide is more effective, less adverse reactions and higher safety, which is a reasonable, effective and safe treatment.